Abstract
In this review, we identify potential targets for the therapeutic effects of heparin in asthma and chronic obstructive pulmonary disease (COPD), consider the safety and delivery modalities of this therapeutic approach. Specifically, we point to the anti-inflammatory, antioxidant and mucolytic effects of unfractionated heparin with potential to modify disease progression in COPD and asthma when administered via the inhaled route. Inhaled heparin may represent an effective add-on therapy in COPD and asthma patient groups, especially when taking into consideration the relative deficiency in endogenous heparin reported in asthma patients.
Original language | English |
---|---|
Pages (from-to) | 39-45 |
Number of pages | 7 |
Journal | Current Opinion in Pharmacology |
Volume | 40 |
Early online date | 20 Feb 2018 |
DOIs | |
Publication status | Published - 1 Jun 2018 |